摘要
目的:探讨循环热灌注化疗治疗胃肠道肿瘤恶性腹腔积液对比单纯灌注化疗的临床疗效、生活质量改善及不良反应的差异.方法:收集本院2010-10/2013-02胃肠道肿瘤伴恶性腹腔积液84例患者,随机分为腹腔循环热灌注化疗组42例(治疗组)及单纯腹腔化疗组42例(对照组),观察两组患者治疗后腹水控制率、生活质量改善、不良反应情况.结果:治疗组腹腔积液控制率为83.33%,对照组腹腔积液控制率59.52%,治疗组显著高于对照组(P<0.05).治疗组治疗后生活质量改善为88.1%,对照组生活质量改善53.76%,治疗组显著高于对照组(P<0.05).两组患者不良反应仅有轻度恶心呕吐、一过性腹痛,I、II度骨髓抑制,无Ⅲ、Ⅳ度毒性,两组对照无差异.结论:循环热灌注化疗较单纯腔内热疗可提高胃肠道肿瘤恶性腹腔积液的控制率,能显著改善患者的生活质量,不良反应轻,值得临床推广应用.
AIM： To compare the curative effect and adverse effects of continuous hyperthermic peritoneal perfusion chemotherapy versus simple intra- peritoneal chemotherapy in the management of malignant seroperitoneum secondary to gastro- intestinal tumors. METHODS： Eighty-four inpatients with ma- lignant seroperitoneum secondary to gastroin- testinal tumors treated at our hospital between October 2010 and February 2013 were enrolled in the study. They were randomly and equally divided into either a study group to undergo continuous hyperthermic peritoneal perfusion chemotherapy or a control group to receive in-traperitoneal chemotherapy. The differences in curative effect, quality of life and adverse effects were compared between the two groups. RESULTS： The rate of ascites control was sig- nificantly higher in the study group than in the control group （88.33% vs 59.52%, P 〈 0.05）. The rate of improvement of quality of life was also higher in the study group （88.1% vs 53.76%, P 〈 0.05）. Adverse effects included mild nausea and vomiting, temporary abdominal pain, CTCAE grade I -Ⅱ bone marrow depression （BMD）, and no grade Ⅲ-Ⅳ BMD was identified. No significant differences in adverse effect were ob- served between the two groups. CONCLUSION： Continuous hyperthermic peritoneal perfusion chemotherapy is superior to simple intraperitoneal chemotherapy in the management of malignant seroperitoneum in terms of ascite control, improvement of quality of life, and adverse effects.
出处
《世界华人消化杂志》
CAS
北大核心
2013年第33期3757-3761,共5页
World Chinese Journal of Digestology
关键词
热灌注化疗
腹腔灌注
恶性腹腔积液
Hyperthermic peritoneal perfusionchemotherapy
Peritoneal infusion
Malignant as-cites
